10th week of 2022 patent applcation highlights part 9 |
Patent application number | Title | Published |
20220071878 | ACIDIC STICK ANTIPERSPIRANTS AND DEODORANTS - Products and methods are disclosed relating to a deodorant stick comprising mandelic acid. | 2022-03-10 |
20220071879 | Late-Stage Product Differentiation Process for Personal Care Products - Process for late-stage differentiation manufacturing of a personal care composition including: formulating a base composition having a first viscosity; comparing the first viscosity of the base composition to a predetermined desired base viscosity range; adjusting the viscosity of the base composition to a second viscosity that is within the desired base viscosity range by addition of one or more viscosity modifiers; and adding one or more differentiation compositions to the base composition to create the personal care composition, wherein the personal care composition has a final viscosity within a desired final viscosity range without the need to add additional viscosity modifiers. | 2022-03-10 |
20220071880 | METHODS FOR TREATING CUTANEOUS AGING - The disclosure relates to methods for treating cutaneous aging by administering to a subject in need thereof a therapeutically effective amount of an aldose reductase inhibitor. | 2022-03-10 |
20220071881 | COSMETIC COMPOSITION COMPRISING HYDROSOLUBLE UV FILTERS - Cosmetic composition comprising hydrosoluble UV filters The present invention relates to a composition, particularly a cosmetic composition, comprising the following in a physiologically acceptable medium: at least one hydrosoluble filter capable of absorbing UV from 320 to 400 nm (UVA) and at least one hydrosoluble filter capable of absorbing UV from 280 to 320 nm (UVB); and at least one thickening agent chosen from among synthetic anionic thickening polymers, non-ionic thickening polysaccharides, sulfated thickening polysaccharides and branched carboxylated thickening polysaccharides. | 2022-03-10 |
20220071882 | TRANSDERMAL DELIVERY COMPLEX USING METAL-ORGANIC FRAMEWORK AND TRIBLOCK COPOLYMER - The present invention relates to a transdermal delivery complex using a metal-organic framework (MOF) and a triblock copolymer. In addition, the present invention relates to a cosmetic composition comprising the transdermal delivery complex and a method for preparing a transdermal delivery complex. | 2022-03-10 |
20220071883 | COMPOSITIONS AND METHODS FOR MODIFYING HAIR COLOR - Compositions and methods for darkening hair of intact skin are presented. Such compositions include defensins in concentrations that are below those that exhibit antimicrobial activity, and can be in the form of a topically applied formulation. Various formulations for such compositions, which can include various pharmaceutically acceptable stabilizers, emollients, and fragrances, are provided. | 2022-03-10 |
20220071884 | DYE COMPOSITION COMPRISING AT LEAST ONE POLYSACCHARIDE-TYPE POLYMER AND PROCESS FOR DYEING KERATIN FIBERS USING SAME - The present application relates to a dye composition comprising at least one polysaccharide-type polymer, at least one fatty ether that is solid at room temperature and atmospheric pressure, of formula R—O—R′ with R and R′, which are identical or different, denoting a linear or branched alkyl or alkenyl radical, R and R′ comprising at least 12 carbon atoms, and at least one direct dye and/or at least one dye precursor. | 2022-03-10 |
20220071885 | SKIN CARE FORMULA, SKIN CARE PRODUCTS, AND METHODS OF MAKING THE SAME - A skin-care aqueous formula includes a guar-based or xantham-based compound, glycerin, and sodium hypochlorite. | 2022-03-10 |
20220071886 | SKIN ENGAGING MEMBER FOR RAZOR CARTRIDGE - This application relates to a razor cartridge including a housing and a skin engaging member, the skin engaging member including a superabsorbent polymer, wherein the superabsorbent polymer is a swellable carrier being loaded with one or more skin active agents. | 2022-03-10 |
20220071887 | NAIL COATING REMOVER CREAM MASK AND THE METHOD OF USING THEREOF - A nail coating remover cream mask comprises a film forming agent from about 5% to about 70% by weight, relative to the total weight of the nail coating remover cream mask, water from about 2% to about 45% by weight, relative to the total weight of the nail coating remover cream mask, a first solvent from about 2% to about 45% by weight, relative to the total weight of the nail coating remover cream mask, a second solvent from about 2% to about 80% by weight, relative to the total weight of the nail coating remover cream mask, a third solvent from about 2% to about 80% by weight, relative to the total weight of the nail coating remover cream mask, and a moisture agent from about 0.1% to about 5% by weight, relative to the total weight of the nail coating remover cream mask, and a method to use the nail coating remover cream mask to remove nail coating. | 2022-03-10 |
20220071888 | TRANSPARENT LIQUID COMPOSITION - A transparent liquid composition that does not substantially contain ethyl alcohol, contains water as the main solvent, and has a high concentration of perfume is provided. | 2022-03-10 |
20220071889 | ANHYDROUS COSMETIC COMPOSITION COMPRISING A LIQUID FATTY SUBSTANCE, A SOLID FATTY SUBSTANCE AND A SURFACTANT - The invention relates to an anhydrous cosmetic composition in foam form comprising, at 25° C. and atmospheric pressure, at least one solid fatty substance, at least one liquid fatty substance and at least one particular surfactant. The invention also relates to a cosmetic process for treating keratin materials, in particular human keratin materials such as the hair and the skin, comprising the application of said anhydrous cosmetic composition. The present invention also relates to the use of said cosmetic composition for washing and/or conditioning keratin materials, in particular human keratin materials such as the hair or the skin. | 2022-03-10 |
20220071890 | SOLID COSMETIC COMPOSITION CONTAINING VEGETABLE BUTTERS - A solid cosmetic composition includes one or more vegetable butters in a total amount of 20 to 80 wt. % based on the cosmetic composition. The composition also has one or more waxes in a total amount of 3 to 4 wt. % based on the cosmetic composition. The composition also includes one or more emulsifying materials in a total amount of 5 to 40 wt. % based on the cosmetic composition. | 2022-03-10 |
20220071891 | Extract of Chlamydomonas Acidophila, Method for Preparing Same and Cosmetic Compositions and Dermatological Compositions Comprising Same - The invention relates to a peptide extract of the microalga | 2022-03-10 |
20220071892 | MITIGATING ADVERSE EFFECTS OF SUNLIGHT WITH INGREDIENTS OBTAINED FROM LIVING PLANTS - Disclosed herein are methods of improving skin appearance associated with skin aging. The method comprises the step of applying an anti-aging bioactive composition to a skin surface having at least one sign of aging. The anti-aging bioactive composition is applied for a period of time sufficient to improve the appearance of the at least one sign of aging. In one embodiment, the anti-aging bioactive composition comprises an effective amount of a | 2022-03-10 |
20220071893 | COMPOSITIONS FOR PREVENTING INFECTION - The present disclosure relates aqueous composition comprising a mucoadhesive polymer and clay particles and methods of treating or preventing infection. | 2022-03-10 |
20220071894 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A CHEMOKINE/CHEMOKINE RECEPTOR INHIBITOR - This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor. | 2022-03-10 |
20220071895 | COMPOSITION AND METHOD FOR TREATMENT OF DIABETES - A method of treating diabetes Type 2, prediabetes, and diseases caused thereby, by delivery of butyric acid, to the colon by bypassing the upper digestive tract wherein release is from 0 to about 5 hours. | 2022-03-10 |
20220071896 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE - Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided. | 2022-03-10 |
20220071897 | USE OF ENCAPSULATED CELL THERAPY FOR TREATMENT OF OPHTHALMIC DISORDERS - Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia. | 2022-03-10 |
20220071898 | DIPIVEFRIN ORALLY DISINTEGRATING TABLET FORMULATIONS - This disclosure provides orally disintegrating dipivefrin tablet (ODT) formulations, including ODT formulations containing L-dipivefrin HCl. The ODT formulations of the disclosure include 10 to 70% binder (wt %), 5 to 50% matrix former (wt %), and 1 to 20% taste masking agent (wt %). The ODT formulations of the disclosure rapidly provide epinephrine to a patient when administered. The disclosure also provides a method of treating a patient who has a condition responsive to epinephrine such as a cardiac event, asthma, croup, cancer, a microbial infection, Addison's disease, or an allergic reaction, particularly anaphylaxis by administering an orally disintegrating dipivefrin tablet formulations to the patient. | 2022-03-10 |
20220071899 | DRINKABLE INFANT COMPOSITIONS - A drinkable infant composition comprising two or more food allergens wherein one of said food allergens is milk protein. | 2022-03-10 |
20220071900 | SYSTEMS AND METHODS FOR PREPARING AND TRANSPORTING AN INJECTABLE SLURRY - The present invention provides for a method of transporting and preparing an injectable ice slurry for administration to a patient at a point of care comprising preparing a biocompatible solution comprising water and at least one component other than water, placing the biocompatible solution into a container, transporting the container with the biocompatible solution to the point of care, transforming the biocompatible solution into an injectable ice slurry at the point of care, and administering the injectable ice slurry to the patient at the point of care. | 2022-03-10 |
20220071901 | A LIQUID FORMULATION OF HUMANIZED ANTIBODY FOR TREATING IL-6-MEDIATED DISEASES - The invention relates to a liquid formulation of humanized antibody for treating IL-6 related diseases. The liquid formulation contains 2-100 mg/ml recombinant humanized anti-human interleukin 6 receptor monoclonal antibody, 5-20 mM histidine salt buffer (or a buffer of a combination of 5-20 mM histidine salt and 5-20 mM sodium acetate), 0.025-0.075% (by volume) surfactant, and 3-5% (by mass to volume) stabilizer and water for injection. The antibody formulation enhances the stability of the recombinant anti-human interleukin 6 receptor monoclonal antibody, prevents the monoclonal antibody from aggregation, degradation, and acidic isomer increases. This formulation can be used for stabilizing the structure and function of the humanized antibody. | 2022-03-10 |
20220071902 | SOLUTION AND METHOD FOR REDUCING THE VIRULENCE OF VIRUSES, BACTERIA, YEASTS, OR FUNGUS - A method of reducing the virulence of microbes in or on the human body and a method of sanitizing or disinfecting a surface, area, object, or porous or non porous material is provided. The methods comprise applying or injecting a solution having an effective amount of a conjugated diene for substantially reducing the virulence of the microbes or sanitizing or disinfecting a surface, area, object, or porous or non porous material. | 2022-03-10 |
20220071903 | POLYVALENT STING ACTIVATING COMPOSITIONS AND USES THEREOF - Described herein are therapeutic pH responsive compositions useful for the treatment of cancer. The compositions involve combining a STING activating polymer micelle, such as PC7A, with a non-peptide STING agonist, such as cGAMP. Methods of administering these compositions in the treatment of cancer are also disclosed. These methods include administration of the pharmaceutical compositions by intratumoral injection in the treatment of solid tumors. | 2022-03-10 |
20220071904 | METHODS OF PROPHYLAXIS OF CORONAVIRUS INFECTION AND TREATMENT OF CORONAVIRUSES - Methods for prophylaxis, treatment, and reduction of infection, re-infection, and transmission rates of Coronaviruses and more particularly Coronavirus Disease 2019 (COVID-19) resulting from a SARS-CoV-2 viral infection with the use of a pharmaceutical preparation comprising one or more coated or uncoated digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes are described herein. | 2022-03-10 |
20220071905 | PEG LIPIDOID COMPOUNDS - The compounds disclosed herein (e.g., compounds having a structure according to Formula (I/(II)/(III)/(IV), and (V)) are polymers wherein an organic polymeric segment (e.g., a polyethylene glycol (PEG) group) comprises covalent attachments to two or more lipid substructures, and each lipid substructure independently comprises a hydrophobic moiety and a hydrophilic moiety. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins. | 2022-03-10 |
20220071906 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR - Disclosed herein are therapeutic constructs including a delivery particle, at least one mitotic kinase inhibitor, and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer-targeted delivery of otherwise toxic therapeutics. | 2022-03-10 |
20220071907 | PRESERVING FUNCTIONALLY-COATED API PARTICLES PRODUCED BY SOLVENTLESS MIXING PROCESSES IN AQUEOUS SUSPENSION - Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions that preserve the coating of coated API particles in a pharmaceutical suspension. Pharmaceutical compositions include coated active pharmaceutical ingredient (API) particles comprising: an API particle; a first coating comprising one or more deformed components coating the API particle; a second coating comprising silica surrounding and/or partially or fully embedded into the first coating, a matrix former, and a structure former. | 2022-03-10 |
20220071908 | POLYMER PARTICLES FOR NEUTROPHIL INJURY - Provided herein are methods of treatment, compositions, systems and kits using polymer particles as restraints of neutrophil function. Such methods include, but are not limited to, methods of preventing, treating, and/or ameliorating inflammatory diseases, infections, autoimmune diseases, malignant diseases, and other diseases or conditions in which neutrophils may be implicated. In some embodiments, polymer particles are useful for diagnosing neutrophil related diseases or conditions. | 2022-03-10 |
20220071909 | MODIFIED RELEASE FORMULATIONS OF LEVODOPA - The present invention relates to modified release formulations of levodopa. Particularly the invention relates to modified release formulation of levodopa that offers reduced dosing frequency. | 2022-03-10 |
20220071910 | Cannabidiol Dosage Form - A dosage form containing an amount of cannabidiol pressed into a tablet. | 2022-03-10 |
20220071911 | LACTOSE POWDER BED THREE DIMENSIONAL PRINTING - Disclosed is the 3D printing of pharmaceutical formulations, such as tablets, wherein a binder liquid is deposited dropwise on a layer of powder, with these steps being repeated, in one or more patterns, in order to generate a solid drug product. In accordance with the invention, the powder comprises lactose particles having a particle size distribution characterized by a D10 of at least 6 μm. | 2022-03-10 |
20220071912 | Enteric Coated Multiparticulate Compositions With A Proteinaceous Subcoat - A method of treating a gastrointestinal disorder includes administering to a patient an effective amount of a multiparticulate dosage form including a plurality of individual spheroidal enteric coated cores having a diameter of 0.1 mm to 3 mm. The individual spheroidal enteric coated cores have (a) a core including menthol, (b) a proteinaceous subcoating over the core, and (c) an enteric coating over the proteinaceous subcoating. The multiparticulate dosage form is configured to release most of the menthol in the area of the GI tract where the inflammation is occurring. | 2022-03-10 |
20220071913 | GRANULE, PREPARATION CONTAINING THE GRANULE, PRODUCTION METHOD OF THE GRANULE, AND PRODUCTION METHOD OF PREPARATION CONTAINING THE GRANULE - One of the objects of the present invention is to provide a granule capable of sufficiently masking bitterness. Alternatively, one of the objects of the present invention is to provide a preparation containing a granule capable of sufficiently masking bitterness. According to an embodiment of the present invention, a granule is provided including a core substance on which a melt component and an active ingredient are disposed, a gelling substance-containing layer disposed on a surface where the melt component and the active ingredient are disposed, and a hydrophobic polymer-containing layer disposed on a surface of the gelling substance-containing layer. | 2022-03-10 |
20220071914 | MICROENCAPSULATION METHOD FOR IMPROVING STABILITY OF ANTHOCYANIN, PRODUCT THERE-FROM AND USE THEREOF - The present invention discloses a microencapsulation method for improving stability of anthocyanin, a product therefrom and use thereof. A preparation method of anthocyanin microcapsules includes: (1) taking sodium alginate as a wall material, adding sodium alginate and calcium carbonate into water, and swelling for 1-2 h to obtain a wall material gel system; (2) taking anthocyanin prepared by a special process as a core material, and fully and uniformly mixing the wall material gel system with an anthocyanin solution to obtain a water phase; (3) mixing Span80 and vegetable oil to obtain an oil phase, mixing the water phase with the oil phase, and magnetically stirring for emulsifying to obtain a W/O emulsion; and (4) adjusting the pH of the W/O emulsion to be acidic, mixing the W/O emulsion with a salt buffer solution, standing for 1-2 h, and then separating the oil phase and the water phase. | 2022-03-10 |
20220071915 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 - The invention relates to mRNA therapy for the treatment of Citrullinemia Type 2 (“CTLN2”). mRNAs for use in the invention, when administered in vivo, encode human Citrin, isoforms thereof, functional fragments thereof, and fusion proteins comprising Citrin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of Citrin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of biomarkers associated with deficient Citrin activity in subjects, namely ammonia and/or triglycerides. | 2022-03-10 |
20220071916 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS - The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid. | 2022-03-10 |
20220071917 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS - The present invention generally relates to particles, including nanocapsules or other nanoentities, comprising a polymer such as polysialic acid. The particles are able to access the interior of the cells, and/or to procure the intracellular release of the associated drugs. In 5 one aspect, the present invention is directed to nanocapsules or other entities having an exterior or surface comprising a polymer such as polysialic acid. In some cases, targeting moieties such as Lyp-1 or tLyp-1 peptide are bonded to the polymer, e.g., using aminoalkyl (C | 2022-03-10 |
20220071918 | MUSSEL ADHESIVE PROTEIN-BASED PHOTOTHERMAL AGENT AND PHOTOTHERMAL- RESPONSIVE ADHESIVE NANOPARTICLES - The present invention relates to: a photothermal agent which includes a mussel adhesive protein; and photothermal-responsive nanoparticles that generate a biocompatible gas by means of light and heat and release a drug. Nanoparticles according to the present invention exhibit a photothermal effect when near-infrared rays are applied thereto, and may be applied to trimodality therapy in which a biocompatible gas is generated by means of light and heat to induce the release of a drug. | 2022-03-10 |
20220071919 | Tellurium Nanostructures with Antimicrobial and Anticancer Properties Synthesized by Aloe Vera-Mediated Green Chemistry - Tellurium (Te) nanostructures are synthesized using green aloe vera chemistry methods, and the synthesized Te tructures provide methods of inhibiting bacterial cells and cancer cells without cytotoxicity towards normal cells. The aloe vera chemistry methods for synthesizing Te nanostructures do not produce toxic byproducts and do not require toxic reagents in comparison to traditional chemical synthetic methods for making Te nanostructures. | 2022-03-10 |
20220071920 | MEMBRANE - The invention relates to a therapeutic composition comprising an inner portion and a biocompatible membrane fully or partially surrounding the inner portion. The biocompatible membrane comprises at least two layers: a first layer of a porous, nonwoven network of thermoplastic polyurethane polymer fibers formed by electrospinning and having a porosity of greater than or equal to 50%; an average pore diameter of less than 5 μm; and has a thickness in the range 10 to 250 μm; and a second layer of a porous, nonwoven network of thermoplastic polymer fibers formed by electrospinning. The second layer has a mean average fiber diameter of the second layer is greater than the mean average fiber diameter in the first layer, and/or wherein the average pore diameter of the second layer is greater than the average pore diameter of the first layer. The inner portion comprises a therapeutic agent. The invention also relates to uses of the membrane and therapeutic composition, for instance, to encapsulate therapeutic cells. | 2022-03-10 |
20220071921 | COMPOUNDS FOR PREVENTING AND TREATING SKIN OR MUCOSAL AFFECTIONS HAVING AN INFLAMMATORY COMPONENT - The present invention concerns the use of selected compounds in a cosmetic skincare treatment or in the treatment of certain skin, scalp or mucosal diseases. The invention also provides a composition for topical use incorporating a pharmaceutically or cosmetically effective amount of a compound for preventing or treating skin or mucosal diseases having an inflammatory component or for reducing the redness or irritation of skin or mucosae. | 2022-03-10 |
20220071922 | DELIVERY OF HEALTH BENEFITS THROUGH COMPONENT FORMULATION - Disclosed are cannabidiol (CBD) formulations with high CBD content for providing a variety of health benefits, and a system for the extraction and packaging thereof. Embodiments include a soothing formulation, an acne treatment formulation, and a sunburn treatment formulation. A method of treating discomfort susceptible to treatment with an anti-inflammatory substance delivered to a site of inflammation is also disclosed. | 2022-03-10 |
20220071923 | COMPOSITIONS AND METHODS FOR TREATMENT OF PEROXISOMAL DISORDERS AND LEUKODYSTROPHIES - Compositions and methods for treating, alleviating, and/or preventing one or more symptoms associated with axonal degeneration in individuals in need thereof, such as individuals with peroxisomal disorders and leukodystrophies include one or more poly(amidoamine) dendrimers G1-G10, preferably G4-G6, complexed with therapeutic, prophylactic and/or diagnostic agent in an effective amount to treat, and/or prevent one or more symptoms associated with axonal degeneration are provided. Compositions are particularly suited for targeted delivery of therapeutics to the affected spinal neurons and may contain one or more additional targeting moieties. | 2022-03-10 |
20220071924 | TREATMENT OF OCULAR DISEASES WITH OPHTHALMIC TAPINAROF COMPOSITIONS - The present invention relates to the treatment of an ocular inflammatory disease or an ocular degeneration disease by ophthalmic administration of a composition comprising tapinarof and optionally at least one additional active agent. Specifically, the ocular inflammatory disease is blepharitis. This invention provides a treatment of blepharitis and Demodex mites. | 2022-03-10 |
20220071925 | MEDICINAL COMPOSITION FOR PREVENTING OR TREATING BONE DISEASES - The present invention provides a pharmaceutical composition useful for preventing or treating a bone disease associated with an abnormality in the balance between osteoclasts and osteoblasts, particularly bone diseases accompanied by inflammation, such as periodontal diseases. The pharmaceutical composition for preventing or treating a bone disease according to the present invention contains a GPR40 agonist and a free fatty acid that is an endogenous ligand of GPR40. | 2022-03-10 |
20220071926 | METHOD FOR PRODUCING XANTHOHUMOL-CONTAINING COMPOSITION - The present invention relates to, for example, a method of producing a xanthohumol-containing composition, including: contacting a first mixture of a hop-derived, xanthohumol-containing component and a first solvent containing water and a water-miscible solvent with polyvinylpolypyrrolidone to adsorb xanthohumol on the polyvinylpolypyrrolidone; washing the polyvinylpolypyrrolidone containing xanthohumol adsorbed thereon with a second solvent; and eluting xanthohumol from the polyvinylpolypyrrolidone with a third solvent to obtain a xanthohumol-containing eluate, wherein the second solvent is an aqueous ethanol solution, and the third solvent is ethanol or an aqueous ethanol solution having a higher concentration than the second solvent. | 2022-03-10 |
20220071927 | IRON/SHIKONIN NANO-COMPOSITE AND USE THEREOF AND METHOD FOR PREPARING THE SAME BY SUPERMOLECULAR SELF-ASSEMBLY - An iron/shikonin nano-composite and a use thereof, and a method for preparing the same by supermolecular self-assembly, belonging to the technical field of functional materials. The composite consists of shikonin and ferric ions, wherein shikonin is coordinated with the ferric ions, and the hydroxyl and carbonyl groups in shikonin are coordinated with the ferric irons to form a complex, which is then assembled by π-π stacking and hydrophobic interactions to form a nano-composite which exhibits glutathione response. The composite is obtained by the following steps: adding an aqueous solution of a ferric salt and an organic solvent solution of shikonin in sequence into water while stirring at ambient temperature, continuously stirring at ambient temperature, and centrifuging the resulting mixture to purify, thereby obtaining an iron/shikonin nano-composite in the resulting solution. | 2022-03-10 |
20220071928 | POLYAMINE TRANSPORT INHIBITORS AS ANTIVIRALS - Disclosed herein are polyamine transport inhibitors (PTI) and methods of use as antivirals. Disclosed PTI compounds are useful as treatments for viral infections or can be used as prophylactic agents that protect high risk individuals from becoming infected by the virus. The disclosed PTI compounds can be used alone or in combination with other agents (or other antivirals) to improve patient outcomes such as DFMO (or Remdesivir). | 2022-03-10 |
20220071929 | APPLICATION OF R-KETAMINE AND SALT THEREOF AS PHARMACEUTICALS - Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(−)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(−)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof. | 2022-03-10 |
20220071930 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2022-03-10 |
20220071931 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2022-03-10 |
20220071932 | Compositions and Methods Against Stress-Induced Affective Disorders and Their Associated Symptoms - Methods for prophylactically treating or treating a stress-induced affective disorder or stress-induced psychopathology in a subject are provided. In certain embodiments, an effective amount of an antagonist of the N-methyl-D-aspartate (NMDA) receptor, such as fluoroethylnormemantine, or a pharmaceutically acceptable salt or derivative thereof, is administered to a subject prior to, during, and/or after, a stressor. | 2022-03-10 |
20220071933 | COMBINATION REMEDY - The present invention primarily relates to a combination agent for reducing appetite and/or for providing a feeling of satiety and/or for reducing energy intake and/or for reducing body weight. In addition, the present invention relates to a medical use of the combination agent, in particular for the treatment of overweight and obesity and for the prevention of cardiovascular disease, stroke, diabetes, and joint damage and wear of the spine, and to a non-therapeutic use of the combination agent. In particular, the focus of the present invention is on the use of the combination agent to provide a feeling of satiety and/or to reduce energy intake and/or to reduce body weight. Finally, the present invention relates to the use of the combination agent for the preparation of an orally consumable preparation or food ingredient and an orally consumable preparation or food ingredient prepared therefrom. | 2022-03-10 |
20220071934 | PHARMACEUTICAL COMPOSITIONS FOR USE IN TREATING PAIN - Provided is a pharmaceutical composition for use in treating postsurgical pain. The pharmaceutical composition comprises a lipid-based complex. The lipid-based complex comprises an amide-type anesthetic and at least one lipid, wherein a molar ratio of the amide-type anesthetic to the at least one lipid of the lipid-based complex is at least 0.5:1. The total amount of the amide-type anesthetic is at least 1.5 to 5 times of a standard therapeutic dose for treating postsurgical pain with the amide-type anesthetic to achieve an improved pain control with desired prolonged analgesic effect. | 2022-03-10 |
20220071935 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE - The present invention provides bumetanide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide analogs and methods for their use. These analogs are believed useful for the treatment and/or prophylaxis of conditions that involve the Na | 2022-03-10 |
20220071936 | CO-CRYSTAL OF KETOPROFEN, COMPOSITIONS COMPRISING THE SAME, PROCESS OF PRODUCING THE SAME, AND USES THEREOF - The present invention refers to a co-crystal of Ketoprofen Lysine named Form 1, a pharmaceutical composition comprising said co-crystal, a process for its production and to its use in the treatment of pain and inflammatory diseases. | 2022-03-10 |
20220071937 | MEDICINAL PROPERTIES OF TRIETHYL CITRATE - This invention describes the potential benefits of chronic oral administration of triethyl citrate (TEC) for the treatment of Alzheimer's disease and atherosclerosis. Evidence is presented that TEC crosses the blood brain barrier via passive diffusion, and the pharmacologic properties of TEC are distinct from administration of citrate salts. Further clinical trials in animal and human subjects is encouraged. | 2022-03-10 |
20220071938 | TREATMENT OF HYPERAMMONEMIA IN PATIENTS WITH RENAL INSUFFICIENCY - Disclosed herein are methods of for treating hyperammonemia in a patient having renal impairment, comprising administering carglumic acid to said patient at a reduced daily dosage. | 2022-03-10 |
20220071939 | COMPOUNDS AND METHODS FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE (PKD) - Described herein are methods for treating PKD in a subject suffering from PKD, the method comprising administering a therapeutically effective amount of at least one compound of the general formula (I), (I) or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein R1-R5 are defined herein. | 2022-03-10 |
20220071940 | Antimicrobial Composition - Provided herein is a method of treating an infectious disease by administering to a patient a pharmaceutical formulation dissolved in aqueous medium having at least one free fatty acid, or a derivative and/or a pharmaceutically acceptable salt of the same, where the free fatty acid has from 6 to 16 carbon atoms, at least one carboxylic acid or a pharmaceutically acceptable salt of the same, and/or at least one carbohydrate or a pharmaceutically acceptable salt of the same. The carbohydrate may be selected from a hydrogenated carbohydrate, a monosaccharide, a disaccharide, a polysaccharide or a combination of the same. The antimicrobial composition provides enhanced anti-adhesion and/or disinfecting properties. The composition may be formulated into a drink, gel or spray, suitable for treating or preventing the first stage in pathogenesis. | 2022-03-10 |
20220071941 | THERAPIES FOR SQUAMOUS CELL CARCINOMAS - The present invention relates to the field of cancer therapy. Specifically, provided are methods of neoadjuvant therapies or adjuvant therapies to treat squamous cell carcinoma in a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on the H-Ras mutant allele frequency. | 2022-03-10 |
20220071942 | MIXED TRIGLYCERIDES - A composition comprising a compound having the formula (1), (2), (3), (4) or combinations thereof, wherein n1, n2, n3, n4, n5 and n6 are independently 4 to 10. | 2022-03-10 |
20220071943 | BISMUTH-THIOL COMPOSITIONS AND METHODS FOR TREATING WOUNDS - The invention relates to bismuth-thiol compounds and pharmaceutical preparations thereof. The invention further relates to methods for treating a topical wound, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a bismuth-thiol compound, wherein the composition is applied to the infection. Methods for treating microbial infections such as diabetic foot infections are also provided. | 2022-03-10 |
20220071944 | Combination Treatment for Solid Tumors Using Docetaxel and a CYP3A Inhibitor - Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More in particular it relates to achieving efficacious doses of orally administered doses docetaxel whilst maintaining acceptable safety. By providing novel means and methods, combining oral docetaxel with a CYP3A inhibitor, the inventors have established improved treatments of cancer, said methods and means providing for an improved safety profile of docetaxel as compared with the standard of treatment for docetaxel, while at the same time allowing to obtain efficacious levels of docetaxel to eradicate cancer cells. | 2022-03-10 |
20220071945 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OCULAR SURFACE DISEASE - Pharmaceutical compositions are described, the compositions comprising an immunosuppressant (such as mycophenolic acid) in combination with a very low concentration of a corticosteroid (such as betamethasone) that are capable of treating, preventing, and/or alleviating an ocular surface disease. Methods for fabricating the compositions and using them are also described. | 2022-03-10 |
20220071946 | Cannabis Treatment of Insomnia, Pain, and Skin Conditions - A pharmaceutical composition for treating one or more symptoms of insomnia is disclosed herein. The pharmaceutical composition includes an amount of cannabidiol (CBD) and an amount of delta-9-tetrahydrocannabinol (THC), wherein the amount of CBD and the amount of THC are effective in treating insomnia. The pharmaceutical composition may include an amount of a selected herb and an amount of another cannabinoid. A pharmaceutical composition for treating one or more symptoms of chronic and acute pain using an amount of CBD and/or THC is also disclosed herein. The pharmaceutical composition may include an amount of another cannabinoid. A pharmaceutical composition for treating one or more symptoms of skin diseases and conditions using CBD and/or THC is also disclosed herein. The pharmaceutical composition may include an amount of another cannabinoid, an essential oil, a permeation enhancer, and/or an anti-bacterial/anti-viral agent. | 2022-03-10 |
20220071947 | PHARMACEUTICAL APPLICATION OF DIMYRICETIN-BASED DISELENIDE - The present disclosure provides a pharmaceutical application of dimyricetin-based diselenide. Dimyricetin-based diselenide has the effect of treating tumors and resistance of new coronavirus, and has obvious inhibitory effects on 7 different human-derived tumor cells. The IC50 value of Mpro, the target of the new coronavirus (2019-nCoV), is 0.807±0.0830 μM, which has a significant effect. | 2022-03-10 |
20220071948 | COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES - The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions. | 2022-03-10 |
20220071949 | COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES - The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions. | 2022-03-10 |
20220071950 | ANTIMICROBIAL COMPOSITIONS COMPRISING CANNABINOIDS AND METHODS OF USING THE SAME - The invention relates is directed to antimicrobial compositions comprising cannabinoid compounds and methods of utilizing the antimicrobial compositions to inhibit the growth of microorganisms, to treat and/or prevent microbial infections. | 2022-03-10 |
20220071951 | THERAPEUTIC AGENT FOR INHERITED BRADYARRHYTHMIA - A therapeutic agent for bradyarrythmia contains the following compound (I) or compound (II) or a pharmacologically acceptable salt thereof as an active component: | 2022-03-10 |
20220071952 | METHODS OF TREATING AND PREVENTING HEPATOTOXICITY - This invention is directed to methods of treating and/or preventing hepatotoxicity and providing hepatoprotection in a subject with dibenzo-alpha-pyrones (DBPs), including 3-OH-DBP (Urolithin B), 3,8-(OH) | 2022-03-10 |
20220071953 | Small Molecule Analogs Of The Protein E4ORF1 In The Treatment And Prevention Of Metabolic Disorders - In an embodiment, the present disclosure pertains to compositions and methods for modulating cellular glucose uptake. In general, the methods include associating cells with the compositions of the present disclosure. In another aspect, the present disclosure pertains to compositions and methods to treat or prevent a disorder in a subject. The methods generally include administering the compositions of the present disclosure to the subject. | 2022-03-10 |
20220071954 | SAROGLITAZAR FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA - The present invention relates to pharmaceutical compositions containing the formula (I) for the prevention, delay of progression, or treatment of a disease or condition from hepatocellular carcinoma. The present invention further provides the composition of formula (I) useful in the prevention and treatment of hepatocellular carcinoma. | 2022-03-10 |
20220071955 | Methods of Treatment, Prevention and Diagnosis - The present invention relates to methods for treating or preventing TDP-43 proteinopathies, such as amyotrophic lateral sclerosis (ALS) and frontotemperal lobar degeneration (FTLD). The present invention also relates to methods of diagnosing TDP-43 proteinopathies. | 2022-03-10 |
20220071956 | COMPOSITION FOR SUPRESSING SECRETION OF EXTRACELLULAR VESICLES - The invention provides a composition for suppressing secretion of extracellular vesicle, which comprises a compound having a structure of the formula II (wherein, each substituent is as defined in the specification), or a pharmaceutically acceptable salt thereof, or a compound having a structure of the formula I (wherein, each substituent is as defined in the specification), or a metal complex thereof, or a pharmaceutically acceptable salt thereof. | 2022-03-10 |
20220071957 | PYRROLE COMPOUNDS - Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof. | 2022-03-10 |
20220071958 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) FOR TREATING DEPRESSION - Provided are compositions for use in treating a patient suffering from a mental disorder in particular major depressive disorder, persistent depressive disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder and psychoactive substance abuse. Further provided are dosing regimens for treating these disorders. | 2022-03-10 |
20220071959 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER - The present invention provides methods and compositions for treating cancer by administering an EP4 antagonist in combination with radiation therapy, antibody therapy and/or anti-metabolite chemotherapy. | 2022-03-10 |
20220071960 | CANCER TREATMENTS - The present invention relates to the use of compounds which display activity as inhibitors of the human N-myristoyl transferases (NMT) in the treatment of MYC addicted cancers, such as, for example, cancers comprising MYC overexpression. The present invention also relates to the use of compounds which display activity as inhibitors of NMT, in combination with one or more other therapeutic agents, in the treatment of MYC addicted cancers and/or MYC dysregulated cancers. | 2022-03-10 |
20220071961 | Dosing Regimen of Bicyclic Substituted Pyrazolone Azo Derivative - A dosing regimen of a bicyclic substituted pyrazolone azo derivative. In particular, the present invention relates to a method for treating a disease, comprising administering to a patient an effective amount of a compound represented by formula I or a pharmaceutically acceptable salt thereof, wherein the interval between administration and food intake is at least 2 hours. | 2022-03-10 |
20220071962 | COMPOSITIONS AND METHODS FOR PROVIDING HEALTH BENEFITS IN AN ANIMAL - The present disclosure provides compositions and methods for providing a health benefit to an animal utilizing ferulic acid and histidine. For example, a composition can contain ferulic acid and histidine in therapeutically effective amounts for providing the health benefit to the animal. | 2022-03-10 |
20220071963 | METHODS AND FORMULATIONS TO TREAT MITOCHONDRIAL DYSFUNCTION - Methods of treatment and pharmaceutical formulations configured to treat primary and secondary mitochondrial dysfunction are provided. The methods and treatments use an agonist of AMPK. The agonist activates AMPK to activate ATP-producing pathways and inhibiting ATP-consuming pathways, thus allowing for the alleviation of symptoms associated with mitochondrial dysfunctions. | 2022-03-10 |
20220071964 | Methods and Compositions for Delivery of Biotin to Mitochondria - Certain exemplary embodiments are directed to a biologically active composition of matter (and uses thereof) configured for targeted delivery of biotin to mitochondria, the composition comprising a first D-biotin conjugated to a water-soluble, cell-permeable, peptide sequence, wherein the peptide sequence is selected from a polypeptide group with an alternating aromatic-cationic motif. | 2022-03-10 |
20220071965 | Pharmaceutical Compositions and Methods Comprising A Combination of a Benzoxazole Transthyretin Stabilizer and an Additional Therapeutic Agent - The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a benzoxazole derivative transthyretin stabilizer or a pharmaceutically acceptable salt or prodrug thereof and an additional therapeutic agent for the treatment of transthyretin amyloidosis. Particularly, the present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or a pharmaceutically acceptable salt or prodrug thereof and one or more additional therapeutic agent for the treatment of transthyretin amyloidosis. | 2022-03-10 |
20220071966 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY - The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway. | 2022-03-10 |
20220071967 | METHOD OF TREATMENT OF SHWACHMAN-DIAMOND SYNDROME - The invention relates to compounds for the treatment of ribosomopathies. In particular, it refers to compounds for the treatment of Shwachman-Diamond Syndrome (SDS) and other ribosomopathies, such as Diamond-Blackfan Anemia (DBA), X-linked dyskeratosiscongenita (DKC) and Treacher Collins syndrome (TCS). | 2022-03-10 |
20220071968 | METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE - This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules. The methods allow shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule. | 2022-03-10 |
20220071969 | TREATMENT OF GASTROPARESIS WITH TRIAZASPIRO[4.5]DECANONE - Provided herein is a method of treating or alleviating one or more symptoms of a disorder, disease, or condition mediated by a dopamine D | 2022-03-10 |
20220071970 | QUINUCLIDINE-3-ONE DERIVATIVES AND THEIR USE IN CANCER TREATMENT - The invention relates to certain substituted quinuclidine-3-one compounds for use in the treatment of hyperproliferative disease, such as cancer, and diseases associated with inflammation. More particularly, the present invention relates to certain substituted 3-quinuclidinones, pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the same, and to methods for using such compounds. In this manner, these compounds are of use for treating hyperproliferative diseases and inflammatory diseases. | 2022-03-10 |
20220071971 | MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE - The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders. | 2022-03-10 |
20220071972 | 5-HYDROXY-7-OXABICYCLO[2.2.1]HEPTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE - The present invention provides 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives of Formula (1) wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds. The compounds are used for inducing chondrogenesis, in methods of treating or preventing joint damage, resulting from joint injury or arthritis, and for inducing hyaline cartilage production. The present description discloses the preparation of exemplary compounds as well as pharmacological data thereof (examples 1 to 89; tables 1 and 2). An exemplary compound is e.g. rac-(1R,2R,3S,4R,5S)-N-(2-fluoro-5-(trifluoromethyl)phenyl)-5-hydroxy-3-(3-(trifluoromethyl)phenyl)-7-oxabicyclo[2.2.1]heptane-2-carboxamid (example 1). | 2022-03-10 |
20220071973 | GEL COMPOSITION WITH AN ANAESTHETIC EFFECT OF SHORT AND LONG TERM DURATION - The present invention is enclosed in the medical area, specifically within the area of lubricant gels for trans-urethral procedures, referring to a gel pharmaceutical composition with an anaesthetic effect of short and long duration, for being administered through the urethra. It is an object of the present invention a gel composition with an anaesthetic effect of short and long term duration for administration through the urethra which comprises a lubricant gel, at least one local short duration anaesthetic composition and at least one local long duration anaesthetic composition which comprises ropivacaine or bupivacaine. The presence of between a long-acting anaesthetic composition in the lubricant gel of the present invention, combined with a short-term acting anaesthetic composition, provides an enormous asset to existing products, because of the immediate and substantially superior and longer-lasting well-being of patients. Advantageously, it is for use as a local anaesthetic with short and long term duration. | 2022-03-10 |
20220071974 | Non-Aqueous Liquid Nimodipine Compositions - Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein. | 2022-03-10 |
20220071975 | DOSAGE REGIMEN OF MDM2 INHIBITOR FOR TREATING CANCERS - The present invention provides a method for treating a cancer in a subject in need thereof, comprising administering a specific MDM2 inhibitor to the subject according to a specific dosage regimen and a pharmaceutical composition for use in treating a cancer according to the dosage regimen. The present invention also provides a method for treating liposarcoma in a subject in need thereof, comprising administering a specific MDM2 inhibitor to the subject and a pharmaceutical composition for use in treating liposarcoma, comprising the MDM2 inhibitor. | 2022-03-10 |
20220071976 | DOMPERIDONE COMPOSITIONS AND METHODS FOR TREATING DEPRESSION - The present invention describes the combination of domperidone with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder. | 2022-03-10 |
20220071977 | READY-TO-ADMINISTER FENTANYL FORMULATIONS - The stable liquid formulations for parenteral administration include fentanyl or a pharmaceutically acceptable salt thereof. The formulations include a diluent and buffer, either containing sodium, in an aqueous solution that has a pH of about 3 to about 4.5. The parenteral liquid formulations are stable formulations that are supplied as a ready-to-administer product in an infusion container or bag. The stable formulations are terminally sterilized in the infusion container. The stable formulations are suitable for administration to a patient in need of therapy with fentanyl or a pharmaceutically acceptable salt thereof. | 2022-03-10 |